This article is more than 5 years old. Information may no longer be current.

Brodalumab effective in patients with psoriasis who failed IL-17A

Patients with moderate-to-severe psoriasis who failed treatment with an IL-17A agent, had significant disease improvement with brodalumab, according to Grace Kimmel, MD, of the Icahn School of Medicine at Mount Sinai, and colleagues.

“This may be due to the unique action of brodalumab, which inhibits the IL-17 receptor, rather than the IL-17a ligand,” Kimmel and colleagues wrote.

Thirty-nine patients with moderate-to-severe psoriasis who had failed treatment with either secukinumab (Cosentyx, Novartis) or ixekizumab (Taltz, Lilly) and were enrolled at three sites were included in the open-label study.

Using the standard dosing schedule, brodalumab 210 mg was administered via subcutaneous injection up to week 16. Patients underwent assessment each month.

After 16 weeks of treatment, the proportion of patients who achieved a static Physician’s Global Assessment (sPGA) sore of ‘0-clear’ or ‘1-almost clear’ served as the primary endpoint. Improvement in Psoriasis Area and Severity Index (PASI) scores was the secondary endpoint.

Among the 34 patients who completed all visits through week 16, the researchers reported PASI-75 scores in 76%, PASI-90 scores in 50% and PASI-100 scores in 32%.

Out of all 39 patients, PASI-75 was achieved in 69%, PASI-90 in 44% and PASI-100 in 28% of patients with 62% achieving sPGA 0 or 1.

Six adverse events occurred, which the researchers determined were unrelated to brodalumab, and no serious adverse events were reported.

“While many factors must be considered in choosing the best treatment for psoriasis patients, efficacy is certainly among the most important,” the researchers wrote. – by Abigail Sutton

Disclosures: Kimmel reports participation in an advisory board for Ortho Dermatologics in October 2018. Please see the study for other authors’ relevant financial disclosures.